Cambrex Co. (NYSE:CBM) CEO Steven M. Klosk sold 55,000 shares of the firm’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $51.73, for a total transaction of $2,845,150.00. Following the completion of the sale, the chief executive officer now directly owns 188,328 shares of the company’s stock, valued at $9,742,207.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Cambrex stock opened at $51.60 on Wednesday. The stock has a market capitalization of $1.72 billion, a P/E ratio of 15.77, a price-to-earnings-growth ratio of 1.27 and a beta of 2.27. Cambrex Co. has a 1 year low of $42.55 and a 1 year high of $62.30.
Cambrex (NYSE:CBM) last issued its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.22. The company had revenue of $141.10 million during the quarter, compared to analyst estimates of $104.44 million. Cambrex had a net margin of 18.69% and a return on equity of 21.00%. Cambrex’s quarterly revenue was up 34.4% compared to the same quarter last year. During the same period last year, the business earned $0.68 EPS. analysts anticipate that Cambrex Co. will post 2.73 earnings per share for the current year.
Several research analysts recently issued reports on CBM shares. Zacks Investment Research upgraded shares of Cambrex from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. ValuEngine upgraded shares of Cambrex from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 26th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $60.00.
Several institutional investors have recently modified their holdings of CBM. Elkfork Partners LLC bought a new position in shares of Cambrex in the 4th quarter worth about $202,000. MML Investors Services LLC bought a new stake in Cambrex during the 4th quarter valued at about $204,000. Two Sigma Securities LLC bought a new stake in Cambrex during the 4th quarter valued at about $207,000. Shaker Investments LLC OH bought a new stake in Cambrex during the 1st quarter valued at about $209,000. Finally, Stevens Capital Management LP bought a new stake in Cambrex during the 1st quarter valued at about $217,000.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.